0
Is olaparib the only PARP inhibitor that has been approved?
- 1 people answered
0 Vote
1 Contributor
1780 Views 
0 Saved
0 Vote 1 Contributor1780 Views 0 SavedYou might also be interested in
It depends on the country. Overdiagnosis relates to the finding of a cancer that doesn’t act in a life-limiting way. Since the beginning of mammography and PSA eras we have diagnosed a lot of such disease.Mammography has not changed the percentage of women who have metastatic disease, rather it has ....
treatment for tumor in the liver depends on the kind of tumor and its extent. please share your reports for a better advice.
When you think about breast cancer, what do you think of? A young woman with nipple discharge? Probably not. And that's because we often associate a lump as a sign of breast cancer, as well as assuming it only affects older women. But what about the other symptoms? There are some lesser known ind....
Rahul Sharma
Yes, PARP inhibitors are relatively newer class of drugs and scientists have just begun to explore their functionality and usage in Cancer treatment. LYNPARZA is the first and only PARP inhibitor approved in 2 distinct settings: For the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. For the treatment of adult patients with suspected deleterious germline BRCA-mutated advanced ovarian cancer which has been treated with 3 or more prior lines of chemotherapy. Patients should be selected for therapy based on an FDA-approved companion diagnostic for LYNPARZA. Poly (ADP-ribose) Polymerase, or PARP, enzymes mediate DNA repair by transferring ADP-ribose units to preexisting ADP-ribose chains on proteins and to proteins. This ADP–ribosylation process recruits DNA repair enzymes, thereby maintaining genomic integrity. Inhibiting this process can lead to the accumulation of DNA damage and, ultimately, cell death.